IPHA Innate Pharma

$IPHA Ok, I’m in with a starter here for data on the 18th. Lots of catalysts over the next few months.

$IPHA in the middle of Nov we should be receive big news do your research on this one can be very big

$IPHA Q3 '26 Earnings Results & Recap Innate Pharma anticipates a cash horizon until the end of Q1 2028; no quantified revenue, margin, or earnings guidance was provided in the third-quarter update.

$IPHA Monalizumab trial results are delayed until H1 2027. This is a mild positive. The trial is fully enrolled and event-driven. Fewer events than expected may mean some good efficacy in at least one arm of the trial (there's another arm, with anti-CD73 Ab).

$IPHA $1.46 Holding long position a loss RETAIN LONG POSITION BRIEF: IPHA said AstraZeneca (AZN) updated the expected high-level data readout for the PACIFIC-9 Phase 3 trial to 1H27 from 2H26 previously. The company said the timing change reflects the event-driven nature of the study; enrollment is complete. PACIFIC-9 is evaluating durvalumab in combination with monalizumab or oleclumab in unresectable Stage III NSCLC after platinum-based chemoradiation. Monalizumab is an anti-NKG2A antibody developed by Innate in collaboration with AstraZeneca.

$IPHA updated the PACIFIC-9 Phase 3 readout timeline to H1 2027, pushing it back from H2 2026.